HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa

Peris, Ketty; Schiavo, Ada Lo; Fabbrocini, Gabriella; Dini, Valentina; Patrizi, Annalisa; Fusano, Marta; Bianchi, Luca; Guanziroli, Elena; Guarneri, Claudio; Parodi, Aurora; Bertoldi, Alberto Maria; Musumeci, Maria Letizia; Offidani, Annamaria; Rongioletti, Franco; Pistone, Giuseppe; Malara, Giovanna; Potenza, Concetta; Casari, Alice; Franchi, C.; Ardigò, Marco; Cusano, Francesco; Stingeni, Luca; Amerio, Paolo; Mancini, Luca; Prignano, Francesca; Deboli, T.; Gualberti, Giuliana; Saragaglia, V.; Bettoli, Vincenzo

doi:10.1111/jdv.15425

Cited by 29 publications

(47 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We herein showed, although in a retrospective study from a single centre, that improvement in HS after adalimumab treatment measured with mSS significantly correlated with QoL evaluated by HIDRAdisk. These results are in line with a recent Italian multicenter study conducted on 140 HS patients which showed significant correlation between HIDRAdisk score and HS severity evaluated through Hurley stage and HS‐PGA . Moreover, similar to a previous study, we demonstrated that treatment led to the highest rates of improvement in HIDRAdisk items such as pain, smell and daily activities.…”

Section: Discussionsupporting

confidence: 92%

“…However, in order to analyse all HS aspects, it is crucial to define the precise burden of the disease and to objectively evaluate the rate of HS improvement at baseline and after therapy. In this context, HIDRAdisk, a simple and innovative visual HS QoL instrument, has been recently psychometrically validated in Italy demonstrating to improve the management of HS once implemented in routine clinical practice . We herein showed, although in a retrospective study from a single centre, that improvement in HS after adalimumab treatment measured with mSS significantly correlated with QoL evaluated by HIDRAdisk.…”

Section: Discussionmentioning

confidence: 63%

“…Due to its chronic nature and frequently occurring relapses, HS has a great impact on patients' QoL . Hence, clinical disease severity assessment is essential for the development of evidence‐based treatments.…”

Section: Discussionmentioning

confidence: 99%

“…Disease tools commonly used to describe patient discomfort such as Dermatology Life Quality Index (DLQI), Skindex‐16, as well as Work Productivity and Activity Impairment (WPAI) are not specific for HS and not useful on large numbers of patients. Recently, a new graphical tool able to better describe HS burden, the so‐called HIDRAdisk, has been introduced . HIDRAdisk is designed to be filled out by the patient with the dermatologist, fostering their communication.…”

Section: Introductionmentioning

confidence: 99%

“…A rewording of the items was performed to further simplify the questionnaire. A multicenter, longitudinal, observational study on 140 patients was therefore conducted to validate the HIDRAdisk compared with other validated questionnaires and to evaluate its correlation with disease severity in patients with different degree of HS severity . HIDRAdisk showed to have a strong correlation with Skindex‐16 and DLQI, and a good one with WPAI.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Age and gender influence on HIDRAdisk outcomes in adalimumab‐treated hidradenitis suppurativa patients

Fabbrocini

Marasca

Megna

et al. 2019

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

Background Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory skin disease characterized by a significant impairment of patients’ quality of life (QoL). It has been recently found that clinical severity of HS does not correlate well with QoL. Therefore, it is important to enhance the evaluation of severity considering the disease burden on QoL. Recently, a new graphical tool able to better describe HS burden, the so‐called HIDRAdisk, has been introduced. Objective To investigate the utility of HIDRAdisk in clinical practice before and after treatment and to analyse whether specific factors such as age and gender may influence the outcomes in patients with moderate‐to‐severe HS. Methods A single‐centre retrospective study on 24 patients (13F/11M, mean age 38 ± 15 years) with moderate‐to‐severe HS was performed. Clinical data (disease severity and quality of life) were collected at baseline and after 12 weeks of adalimumab. Results HIDRAdisk showed significantly better improvements in males (69.8 ± 6.2–49.6 ± 10.8) compared to females (80.7 ± 6.0–72.3 ± 6.7), P <0.001. A significant correlation was found in the total population between HS severity values measured through the modified Sartorius score (mSS) and QoL measured through HIDRAdisk. As regards the relationship between disease outcomes and age, a trend for better HIDRAdisk outcomes in younger patients (<40 years) compared to older ones was observed. Conclusions HIDRAdisk appears as a complete and informative tool which can easily measure the global burden of HS, guiding treatment choice and evaluating its efficacy.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 63%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Age and gender influence on HIDRAdisk outcomes in adalimumab‐treated hidradenitis suppurativa patients

Fabbrocini

Marasca

Megna

et al. 2019

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

show abstract

Assessing severity, treatment response, and phenotype in HS

Buechler

Daveluy

2022

Dermatological Reviews

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by recurrent abscesses, nodules, tunnels, and scarring in intertriginous areas. However, disease presentation and phenotype can vary widely, leading to unique challenges in determining disease burden and response to therapy. Over three dozen severity measures have been used at various times to provide static staging and track response to clinical interventions, and there are at least five proposed classification systems for clinical phenotypes, derived by either statistical methods or expert opinion. As yet, no single staging, outcome-measurement, or phenotyping schema has proven to be far superior to the others in clinical practice, and very few studies have attempted to map proposed phenotypes to either outcome or clinical response to therapy. In this review, we discuss proposed phenotype schemas as well as provider-scored, patient-scored, and composite scoring systems that have been proposed for grading HS severity. We include relevant benefits and drawbacks to their routine use, with a focus on the most popular and recently developed systems, in the hope of providing a framework upon which future studies can be built to ensure the best possible care for those suffering from this debilitating disease.

show abstract

Quality of life in Hidradenitis Suppurativa (Acne Inversa): A scoping review

Kaur¹,

Laing²,

Griffin³

et al. 2023

Skin Health and Disease

View full text Add to dashboard Cite

Background Hidradenitis Suppurativa (HS) is a chronic, relapsing, inflammatory skin condition which is physically, psychologically and socially disabling and often affects a patient's quality of life (QOL). There are numerous QOL tools used in dermatology. However, assessment of QOL in patients with HS is difficult due to the inability of generic QOL tools to specifically capture QOL in patients with HS. Numerous HS‐specific QOL tools have been developed in recent years. It is important to identify evidence on full psychometric evaluation of these tools. Objectives There has been a gradual increase in the use of generic and disease‐specific QOL tools in the last few decades. The aim of this scoping review (SR) is to evaluate the most widely used generic QOL tools and HS‐specific QOL tools to identify the psychometric evaluation of such tools. Methods Design: An SR guided by Joanna Briggs Institute manual and Arskey O’Malley framework guidelines. Data extraction included the studies available on full psychometric evaluation of the most widely used dermatology generic QOL tools in HS and HS‐specific QOL tools. Results Ten papers were included in the review, eight papers demonstrated HS‐specific QOL assessment tools. The psychometric properties of these tools were underpinned by reliability, validity and sensitivity measurement. Six disease‐specific tools were identified in this SR. However, they all lack full psychometric evaluation. Conclusion This review indicates that an extensive research in the field of QOL tools for HS is much needed. It is crucial to develop user‐friendly and validate disease‐specific tools to measure the real impact of disease on patients QOL. QOL instruments can evaluate the impact on life of an HS patient, thus helping improve intervention and management of disease. There is a necessity for more research into existing HS‐specific QOL tools and they should be widely tested and fully validated.

show abstract

HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa

Cited by 29 publications

References 21 publications

Age and gender influence on HIDRAdisk outcomes in adalimumab‐treated hidradenitis suppurativa patients

Age and gender influence on HIDRAdisk outcomes in adalimumab‐treated hidradenitis suppurativa patients

Assessing severity, treatment response, and phenotype in HS

Quality of life in Hidradenitis Suppurativa (Acne Inversa): A scoping review

Contact Info

Product

Resources

About